PAPER

Correlation between clinical characteristics and proliferative activity in patients with craniopharyngioma

M Losa, A Vimercati, S Acerno, R L Barzaghi, P Mortini, F Mangili, M R Terreni, G Santambrogio, M Giovanelli

J Neurol Neurosurg Psychiatry 2004;**75**:889–892. doi: 10.1136/jnnp.2003.012781

See end of article for authors' affiliations

Correspondence to:
Dr M Losa, Department of
Neurosurgery, Istituto
Scientifico San Raffaele,
Via Olgettina 60,
20132-Milan, Italy;
losa.marco@hsr.it

Received 14 February 2003
Revised 7 October 2003
Accepted 17 October 2003

Objectives: The aim of the study was to correlate the Ki-67 and cyclin A labelling index (LI) with clinical characteristics and risk of recurrence of craniopharyngiomas.

Methods: 47 consecutive patients were studied, 21 female and 26 male, aged 34.3 (2.8) years. Immunohistochemical analysis was performed on paraffin wax embedded material using monoclonal antibodies directed against the proliferation associated nuclear antigen Ki-67 and cyclin A.

Results: The median Ki-67 LI was 8.6% (interquartile range, 4.4%–14.0%). Ki-67 LI was significantly higher in tumours with a heavy inflammatory reaction and diabetes insipidus at presentation, whereas other clinical and histological features were not associated with the proliferation index. There was a strong linear correlation between Ki-67 LI and cyclin A LI ($r=0.77$; $p<0.0001$); therefore, cyclin A LI showed the same clinical and histological relations described for Ki-67 LI. Recurrence of craniopharyngioma occurred in 13 of 46 patients (28.3%). The median Ki-67 LI in the 13 recurrent craniopharyngiomas (9.0%) was not significantly different from that of non-recurring tumours (7.9%). Cyclin A LI was also not associated with the risk of relapse.

Conclusions: This study confirms the great variability of proliferative activity in craniopharyngiomas. Ki-67 and cyclin A LIs were associated with the presence of a heavy inflammatory reaction and diabetes insipidus, but did not correlate with the long term risk of tumour regrowth.

Craniopharyngiomas are histologically benign tumours of the sellar region that account for 1.2% to 4.6% of all intracranial tumours. Their annual incidence is 0.5 to 2.5 cases per million population.^{1,2} There is a bimodal age distribution of incidence rates with a first peak in patients aged 5 to 14 years and a second peak between the ages of 50 and 74 years.^{2,3} Surgical removal of the lesion is the first choice treatment, whereas radiation therapy is usually reserved to diminish the risk of recurrence in patients with incomplete tumour resection. Reliable objective morphological criteria for predicting tumour behaviour are, however, still lacking.

Ki-67 is a nuclear antigen expressed in all phases of the cell cycle except G0.^{4,5} Expression of Ki-67 is a requirement for cells to traverse the cell cycle and undergo cell division⁶ and, therefore, all types of proliferating human cells express Ki-67.⁷ The cyclins are proteins that play an important part in the control of cell proliferation, being essential for passage through specific stages of the cell cycle.⁸ In particular, cells expressing cyclin A are committed to cell division.⁹ Therefore, determination of the cells expressing cyclin A might represent a more specific measure of the growth fraction of a specified tissue.

The aim of our study was to measure the Ki-67 labelling index (LI) and cyclin A LI in a consecutive series of patients with craniopharyngioma.

METHODS

Patients

Tumour specimens were obtained from 47 consecutive patients with craniopharyngioma, operated on between January 1990 and December 2000 at our hospital. The study included 21 female patients (45%) and 26 male patients (55%) with a mean (SE) age of 34.3 (2.8) years, ranging from 6 to 78 years. Sixteen patients (34.0%) were ≤ 18 years of age

at the time of surgery. Ten patients had previously been operated (two by us and eight in other hospitals). The reason for surgery was recurrence of the tumour in three cases and unsuccessful removal in the remaining seven patients. Only one patient had received radiation therapy before surgery.

Presenting symptoms, hormonal, and neuroradiological data were prospectively recorded for each patient. Follow up included first postoperative magnetic resonance imaging (MRI) two to six months after surgery and then at variable intervals, depending on the clinical and neuroradiological situation. Recurrence of craniopharyngioma during follow up was defined as evidence at repeat MRI of pathological tissue not detected earlier or growth of residual neoplastic tissue in comparison with the previous MRI.

Histological analysis

Surgically removed specimens were fixed immediately in 10% buffered formalin and subsequently embedded in paraffin wax. Standard haematoxylin and eosin sections were used for diagnosis. Craniopharyngiomas were subdivided into adamantinomatous and papillary tumours. Tumours with mixed characteristics were classified as adamantinomatous type.

MIB-1 and cyclin A immunostaining

Ki-67 antigen was detected by means of the monoclonal antibody MIB-1, which can be used in formalin fixed paraffin wax embedded specimens. MIB-1 and cyclin A immunostaining were performed using the avidin-biotin-peroxidase complex method on 4 μ m thick sections serially obtained from the paraffin wax embedded tissue. Antigen retrieval was obtained by microwave treatment (two passages at 850 Watts of five minutes each). MIB-1 monoclonal antibody

Abbreviations: LI, labelling index; MRI, magnetic resonance imaging

diluted 1:50 (Immunotech SA, Marseille, France) or anti-cyclin A monoclonal antibody diluted 1:100 (Amersham) were used as primary antibodies. No MIB-1 or cyclin A antisera were added on sections used as negative controls. The Ki-67 and cyclin A LIs were determined by a single pathologist (FM), who was unaware of the clinical characteristics of the patients. A total of at least 1000 neoplastic nuclei, subdivided in 10 fields chosen randomly at $\times 400$ magnification, were counted.

Statistical analysis

Ki-67 LI and cyclin A LI were transformed logarithmically before statistical analysis, because they were not normally distributed. However, in the text and figures Ki-67 LI and cyclin A LI are given in the more usual decimal format. Continuous data are expressed as mean (SE), except for Ki-67 LI and cyclin A LI, which are presented as median values with interquartile ranges. Student's *t* test for unpaired data was used to compare continuous variables among groups. Correlation coefficient between Ki-67 LI and cyclin A LI was calculated by the method of least squares. Stepwise regression analysis was used to test the association between Ki-67 LI and clinical and histological characteristics of the patients. The Kaplan-Meier method was used to analyse the primary end point of recurrence of craniopharyngioma during follow up. Recurrence free survival was measured from the date of surgery to the date of relapse and was censored at the date of the last MRI follow up.

A *p* value of less than 0.05 was considered to indicate significance.

RESULTS

Ki-67 and cyclin A LIs

Table 1 summarises the clinical characteristics of the study population. The median Ki-67 LI in all patients was 8.6% (4.4%–14%). Table 2 shows the univariate analysis of the associations between Ki-67 LI and several clinical characteristics of the patients. Because of the possible relations among some of the variables, we then construed a multivariate analysis, including in the model those variables that had a $p < 0.10$ in the univariate analysis plus age and maximum tumour diameter. Stepwise regression analysis showed that only heavy flogistic reaction ($p < 0.01$) and diabetes insipidus at presentation ($p < 0.01$) were independently and positively associated with a high Ki-67 LI, whereas age, maximum tumour diameter, and histological subtype had no independent value.

Cyclin A LI could not be evaluated in three samples because of technical failure. The median cyclin A LI in the remaining 44 patients was 3.6% (1.5%–6.6%). There was a strong linear correlation between Ki-67 LI and cyclin A LI ($r = 0.77$; $p < 0.0001$; fig 1). Because of the strong correlation between the two variables, cyclin A LI showed the same relations described for Ki-67 LI with clinical and histological variables.

Ki-67 and cyclin A LIs and the risk of recurrence

One patient died one week after operation because of hypothalamic derangement. Mean (SE) follow up for the remaining 46 patients was 60.4 (5.2) months, ranging from 3 to 141 months. The first postoperative MRI showed no residual tumour in 29 patients (63.0%), whereas pathological tissue was present in the remaining 17 patients (37.0%).

Recurrence of craniopharyngioma occurred in 13 of the 46 patients (28.3%). The disease free interval at five years was 69.6% (95% confidence intervals, 55.0% to 84.3%). The median Ki-67 and cyclin A LIs in the 13 recurrent craniopharyngiomas (9.0% and 2.9%, respectively) were not significantly different from that of non-recurrent tumours

Table 1 Clinical characteristics of patients operated for a craniopharyngioma

Characteristics	n = 47
Female sex (%)	21 (44.7)
Age (y) (SE)	34.3 (2.8)
Hypogonadism (%)	36 (76.2)
Hypothyroidism (%)	23 (48.9)
Hypoadrenalsim (%)	23 (48.9)
Diabetes insipidus (%)	20 (42.5)
Visual defects (%)	40 (85.1)
Mass effect symptoms (%)	12 (25.5)
Maximum tumour diameter (mm) (SE)	32.1 (1.7)
Cystic tumour (%)	43 (91.5%)
Tumour calcifications (%)	26 (55.3)
Suprasellar extension (%)	45 (95.7)
Transcranial approach (%)	40 (85.1)
Apparent complete removal (%)	33 (70.2)
Adamantinomatous subtype (%)	44 (93.6)
Infiltration of nervous tissue (%)	6 (12.8)
Infiltration of pituitary (%)	5 (10.6)
Flogistic infiltration of the tumour (%)	10 (21.3)

(7.9% and 5.0%, respectively). Both Ki-67 and cyclin LIs had no independent prognostic value on the risk or recurrence either when computed as continuous or categorical variables (fig 2).

DISCUSSION

Despite their benign histological nature, craniopharyngiomas may behave aggressively and recur even after apparent complete surgical removal. The median Ki-67 LI in our study population was 8.6%, with a wide range of values, from 0.1% to 40%. Other studies found a mean (SD) Ki-67 LI of 10.8 (8.0)% and 7.8 (7.9)% in 17 and 37 patients, respectively.^{10 11} In another study involving only children, the mean (SD) Ki-67 LI was 4.7 (2.3)%.¹² To put these values into perspective, pituitary adenomas, the most frequent benign tumour of the pituitary gland, seem to have a lower proliferation activity.^{13–15}

Among several characteristics, only presence of a strong inflammatory reaction and diabetes insipidus at presentation were independently associated with high Ki-67 LI. It is possible that craniopharyngiomas with a high proliferative index may induce a strong inflammatory reaction. It is more difficult to explain the apparent association between diabetes insipidus and Ki-67 LI. One possible explanation is that diabetes insipidus is a surrogate marker for an infiltrating and more aggressive tumour behaviour. However, we caution against overinterpretation of these results because of the small sample size of the study population.

Cyclin A LI was almost 50% lower than Ki-67 LI and strongly correlated with it. This finding implies that in craniopharyngiomas most cells entering the mitotic cycle proceed until the late stages of the cycle with few losses. Therefore, measurement of cyclin A does not add more information than that obtained by Ki-67 LI determination alone.

As for other benign tumours of the sellar region, the factors contributing to the long term prognosis are complex. Tumour recurrence is one of the most fearful complications in patients operated for a craniopharyngioma and has strong adverse consequences on survival and quality of life. Recurrence rates from 5% to 57% have been reported in large series of craniopharyngiomas.^{3 12 16–26} The variability of the reported recurrence rates is probably attributable to various factors, such as different definitions of recurrence (clinical or neuroradiological), whether surgery was aimed at total or partial removal of the tumour and whether radiation therapy

Table 2 Association of Ki-67 LI with various clinical characteristics in 47 patients operated on for craniopharyngioma

Variables		Median Ki-67 LI (25–75 interquartile range) (%)	p Value
Sex	Male (n=26)	7.1 (3.6–14.0)	0.84
	Female (n=21)	9.0 (6.6–14.3)	
Adult	Yes (n=31)	8.6 (4.1–13.5)	0.87
	No (n=16)	8.4 (5.3–14.9)	
Previous surgery	Yes (n=10)	9.7 (4.4–14.0)	0.62
	No (n=37)	8.5 (4.4–12.5)	
Diabetes insipidus	Yes (n=20)	10.2 (8.7–20.5)	0.03
	No (n=27)	6.3 (3.5–9.1)	
Cystic tumour	Yes (n=43)	8.9 (4.9–14.0)	0.72
	No (n=4)	5.4 (3.1–9.6)	
Retrosellar extension	Yes (n=12)	9.5 (6.1–14.9)	0.64
	No (n=35)	8.5 (3.7–13.5)	
Tumour calcification	Yes (n=26)	8.8 (4.6–10.0)	0.86
	No (n=21)	8.5 (4.3–18.7)	
Papillary subtype	Yes (n=3)	25.0 (15.2–36.2)	0.01
	No (n=44)	8.1 (4.2–12.2)	
Flogistic reaction	Yes (n=10)	16.5 (9.2–24.0)	<0.001
	No (n=37)	7.0 (3.6–10.1)	

was advised or not postoperatively. The recurrence rate in our study was 28% and almost all recurrences occurred within three years from surgery. The tendency to early recurrence has already been noted in other series.^{12–16}

Our study failed to show any association between the proliferation activity of the tumour, assessed either by means of Ki-67 LI or cyclin A LI, and the risk of relapse. Our results are in agreement with those of others,^{11–12} but in contrast with those of Nishi and coworkers¹⁰ who, in their series of 17 patients, identified a Ki-67 LI greater than 7% as strongly predictive of tumour recurrence. However, in the second study¹⁰ there was an unusually high rate of recurrence (76.5%) compared with our data (28.3%). It is noteworthy that the same failure of Ki-67 LI to predict tumour recurrence has occurred in a similarly designed study involving patients with non-functioning pituitary adenomas¹³ and in odontogenic tumours, which share several histological and behavioural characteristics with craniopharyngiomas.²⁷

In conclusion, our study confirms the great variability of proliferative activity in craniopharyngiomas. Both Ki-67 LI and cyclin A LI were associated with the presence of

inflammatory reaction and diabetes insipidus, but did not correlate with the long term risk of tumour regrowth. Therefore, our data do not support the routine use of both variables to identify patients at higher risk of recurrence.

Figure 1 Correlation between Ki-67 LI and cyclin A LI (shown as raw data) in 44 patients with craniopharyngioma. Regression analysis on log transformed data demonstrates a strong positive association between the two variables ($r=0.77$; $p<0.0001$). The regression equation is $y=0.836x-0.201$.

Figure 2 Kaplan-Meier analysis of the effect of Ki-67 (upper panel) and cyclin A (lower panel) LIs on the risk of recurrence of craniopharyngiomas. Both Ki-67 and cyclin A have been categorised according to their median value (8.6% and 3.6%, respectively). There was no significant difference according to the log rank test ($p=0.37$ and $p=0.07$, respectively). Similar results were obtained when Ki-67 and cyclin A LIs were categorised according to their 25% or 75% values.

ACKNOWLEDGEMENTS

We thank Dr G Calori of the Clinical Epidemiology Unit of Istituto Scientifico San Raffaele for statistical advice.

Authors' affiliations

M Losa, A Vimercati, S Acerno, R L Barzaghi, P Mortini, M Giovannelli, Pituitary Unit, Department of Neurosurgery, Istituto Scientifico San Raffaele, University Vita-Salute, Milan, Italy

F Mangili, M R Terreni, G Santambrogio, Department of Pathology, Istituto Scientifico San Raffaele

Funding: none

Competing interests: none declared

REFERENCES

- 1 Zülch K. *Brain tumors. Their biology and pathology*. New York: Springer-Verlag, 1986.
- 2 Bunin GR, Surawicz TS, Witman PA, et al. The descriptive epidemiology of craniopharyngioma. *J Neurosurg* 1998;**89**:547–51.
- 3 Szeifert GT, Sipos L, Horváth M, et al. Pathological characteristics of surgically removed craniopharyngiomas: analysis of 131 cases. *Acta Neurochir (Wien)* 1993;**124**:139–43.
- 4 Losa M, Franzin A, Mortini P, et al. Usefulness of markers of cell proliferation in the management of pituitary adenomas. *Clin Sci* 1998;**95**:129–35.
- 5 Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol* 2000;**182**:311–22.
- 6 MacCallum DE, Hall PA. The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. *J Pathol* 2000;**190**:537–44.
- 7 Hall PA, Woods AL. Immunohistochemical markers of cellular proliferation: achievements, problems and prospects. *Cell Tissue Kinet* 1990;**23**:505–22.
- 8 Prosperi E, Stivala LA, Scovassi AI, et al. Cyclins: relevance of subcellular localization in cell cycle control. *Eur J Histochem* 1997;**41**:161–8.
- 9 Desdouets C, Sobezack-Thépot J, Murphy M, et al. Cyclin A: function and expression during cell proliferation. *Prog Cell Cycle Res* 1995;**1**:115–23.
- 10 Nishi T, Kuratsu JI, Takeshima H, et al. Prognostic significance of the MIB-1 labeling index for patient with craniopharyngioma. *Int J Mol Med* 1999;**3**:157–61.
- 11 Ravaghan R, Dickey WT Jr, Margraf LR, et al. Proliferative activity in craniopharyngiomas: clinicopathological correlations in adults and children. *Surg Neurol* 2000;**54**:241–8.
- 12 Kim S-K, Wang K-C, Shin S-H, et al. Radical excision of pediatric craniopharyngioma: recurrence pattern and prognostic factors. *Childs Nerv Syst* 2001;**17**:531–6.
- 13 Losa M, Franzin A, Mangili F, et al. Proliferation index of nonfunctioning pituitary adenomas: Correlations with clinical characteristics and long-term follow-up results. *Neurosurgery* 2000;**47**:1313–19.
- 14 Losa M, Barzaghi R, Mortini P, et al. Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors: comparison between micro- and macroadenomas. *Am J Pathol* 2000;**156**:245–51.
- 15 Losa M, Ciccarella E, Mortini P, et al. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. *J Clin Endocrinol Metab* 2001;**86**:5194–200.
- 16 Duff JM, Meyer FB, Ilstrup DM, et al. Long-term outcomes for surgically resected craniopharyngiomas. *Neurosurgery* 2000;**46**:291–305.
- 17 Adamson TE, Wiestler OD, Kleihues P, et al. Correlation of clinical and pathological features in surgically treated craniopharyngiomas. *J Neurosurg* 1990;**73**:12–17.
- 18 Carmel PW, Antunes JL, Chang CH. Craniopharyngiomas in children. *Neurosurgery* 1982;**11**:382–9.
- 19 Stahnke N, Grubel G, Lagenstein I, et al. Long-term follow-up of children with craniopharyngioma. *Eur J Pediatr* 1984;**142**:179–85.
- 20 Fischer EG, Welch K, Shillito J Jr, et al. Craniopharyngiomas in children. Long-term effects of conservative surgical procedures combined with radiation therapy. *J Neurosurg* 1990;**73**:534–40.
- 21 Yasargil MG, Curcic M, Kis M, et al. Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. *J Neurosurg* 1990;**73**:3–11.
- 22 Weiner HL, Wisoff JH, Rosenberg ME, et al. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. *Neurosurgery* 1994;**35**:1001–11.
- 23 Crotty TB, Scheithauer BW, Young WF, et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. *J Neurosurg* 1995;**83**:206–14.
- 24 Eldevik OP, Blaivas M, Gabrielsen TO, et al. Craniopharyngioma: radiologic and histologic findings and recurrence. *Am J Neuroradiol* 1996;**17**:1427–39.
- 25 Villani RM, Tomei G, Bello L, et al. Long-term results of treatment for craniopharyngioma in children. *Childs Nerv Syst* 1997;**13**:397–405.
- 26 Fahlbusch R, Honegger J, Paulus W, et al. Surgical treatment of craniopharyngiomas: experience with 168 patients. *J Neurosurg* 1999;**90**:237–50.
- 27 Slootweg PJ. p53 protein and Ki-67 reactivity in epithelial odontogenic lesions. An immunohistochemical study. *J Oral Pathol Med* 1995;**24**:393–7.